BRIEF-ContraVir to highlight clinical data from phase 2a study of tenofovir exalidex for treating hepatitis B

* ContraVir to highlight clinical data from ongoing phase 2a study of tenofovir exalidex (TXL) for treating hepatitis B
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.